IL1B and rheumatoid arthritis: Replicating even this degree of success in the clinic has proved difficult in clinical trials of alternative agents, for example blocking IL-1β, IL-17 and the IL-12/23 family in rheumatoid arthritis – despite their attractiveness as targets [8–10].